The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Jul. 24, 3:22 PM

Slide #18. Genocea Biosciences, Inc. Secondary Offering

Company: Genocea Biosciences, Inc. (NASDAQ:GNCA)
Date announced: 7/14/2014
Shares Offered: 3,400,000
Secondary Offering Details: Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that it has commenced an underwritten public offering of 3,400,000 shares of its common stock. All the shares in the offering will be sold by Genocea.

Genocea Biosciences is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today. Co. uses its proprietary discovery platform, ATLAS, to rapidly design vaccines that act through T cell (or cellular) immune responses, in contrast to approved vaccines, which are designed to act primarily through B cell (or antibody) immune responses. Co. has announced human proof-of-concept data for GEN-003, an immunotherapy, or therapeutic vaccine, candidate that Co. is developing to treat herpes simplex virus-2, or HSV-2, infections.
Open the GNCA Page at The Online Investor »

Company Name:  Genocea Biosciences Inc
Website:  www.genocea.com
Sector:  Biotechnology
Number of ETFs Holding GNCA:  10
Total Market Value Held by ETFs:  $1.75M
Total Market Capitalization:  $262.00M
% of Market Cap. Held by ETFs:  0.67%
 

Open the GNCA Page at The Online Investor (in a new window) »

July 24, 2014    3:22 PM Eastern
Quotes delayed 20 minutes



Strong Buy (3.67 out of 4)
79th percentile
(ranked higher than approx. 79% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.